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Early Evolution of Plasma Soluble TNF- p75 Receptor 
as a Marker of Progression in Treated 
HIV-Infected Patients
P. Morlat,1,2 E. Pereira,2 P. Clayette,3 N. Derreudre-Bosquet,3 J-L. Ecobichon,4 O. Benveniste,5
M. Saves,2 C. Leport,4 and the ANRS CO8 Aproco-Copilote Study Group*
Abstract
We evaluated the prognostic value of different mediators of inflammation: TNF- and its soluble receptor p75,
platelet-activating factor, and glutathione tripeptide in a case–control study nested within a cohort of 1281 pa-
tients infected by the human immunodeficiency virus (HIV) started on highly active antiretroviral treatment
(HAART). During the first year of HAART, 16 cases experienced an AIDS-defining event and 6 experienced an
evolution of T CD4 cell count 100/mm3. Forty-four controls who did not progress during the same follow-
up period were matched for age, baseline CD4, and HIV-RNA. In the control group, plasma levels of TNF-
and its soluble receptor p75 decreased significantly from baseline to month 4: from 11.0 to 8.7 pg/ml (p  0.001)
and from 27.3 to 22.8 pg/ml (p  0.003), respectively. Furthermore the decrease of TNF- and its soluble 
receptor p75 was larger in nonprogressors than in progressors (p  0.003). Measurement of TNF- soluble re-
ceptor p75 may be of interest as an additional marker of early antiretroviral effect.
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Introduction
THE CHRONIC IMMUNE ACTIVATION SPECIFIC TO HIV DISEASEcontributes to HIV disease pathogenesis. Several cohorts
have already shown the prognostic value of plasma levels of
tumor necrosis factor- (TNF-) and especially of its soluble
TNF- p75 receptor (sR-TNF- p75) for HIV disease pro-
gression.1–7 These studies were mainly conducted before the
era of highly active antiretroviral therapy (HAART) and in-
formation is lacking on the relationship between sR-TNF-
p75 or other immune markers with clinical progression in
patients receiving HAART. In a previous study, we showed
a correlation between the evolution of plasma levels of im-
mune markers, especially sR-TNF- p75, and simultaneous
immunovirological responses in HAART-treated patients.
However, this study did not assess the prognostic role of
early variations of these markers on HIV disease progres-
sion.8
In addition, the prognostic role of other inflammatory me-
diators remains currently unknown. The platelet-activating
factor (PAF; 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphoryl-
choline) may play a role in inflammatory and immune re-
sponses9 and some of its antagonists had in vitro antiretro-
viral properties.10,11 Inflammatory processes triggered by
PAF are mediated by interactions with a specific PAF re-
ceptor12 and restrained by a enzymatic PAF-inactivating sys-
tem, including plasma PAF acetylhydrolases (PAF-AH) that
catalyzes the hydrolysis of the sn-2 ester bond of PAF.13 Be-
cause PAF-AH is important for regulation of plasma PAF
concentration, the dosage of plasma PAF activity is consid-
ered more reliable than PAF. Oxidative stress may also con-
tribute to inflammatory processes in HIV disease and may
be measured either by the major antioxidant in the organ-
ism, the glutathione tripeptide (GSH or L--glutamyl-L-cys-
teinylglycine),14 whose low level is associated with poor sur-
vival in HIV-infected patients,15 or the activity of GSH
peroxidases (GSH-Px), which oxidizes GSH in its disulfide
form (GSSG). GSH-Px associated with superoxide dismu-
tases (SOD) is an important initial component in cellular de-
fenses against reactive oxygen species (ROS) toxicity, e.g.,
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superoxide anions (O2°–) and hydrogen peroxide (H2O2).
Moreover, HIV, by subverting the intracellular cysteine pool
for its own replication, is able to decrease GSH biosynthe-
sis16 and to generate a production of inflammatory media-
tors such as TNF-.17
In the context of the well-validated surrogacy value of
CD4 lymphocyte count and plasma HIV-RNA levels, which
are the cornerstones of the laboratory follow-up in HIV-in-
fected treated patients, we assessed the potential additive
prognostic value of plasma levels of TNF, sR-TNF- p75,
PAF-AH, GSH, and GSH-Px on the progression of HIV in-
fection in HAART-treated patients.
Materials and Methods
The study was a case–control study nested within the
APROCO-COPILOTE cohort. This cohort is a prospective
study of the French National Agency for Research on AIDS
and viral hepatitis (ANRS CO8) that enrolled consecutively
adult HIV-infected patients who for the first time started a
protease inhibitor (PI)-containing regimen in 1997–1998 and
were followed in 47 French clinical wards.18 Standardized
clinical and biological data are collected at baseline, 1 and 4
months after enrolment, and every 4 months thereafter. In-
vestigators are requested to report clinical progression and
deaths to the coordinating center as soon as they are known.
In the current analysis, cases (i.e., rapid progressors) were
defined as patients who experienced HIV disease progres-
sion during the first year of treatment. Disease progression
was defined as an occurrence of a new AIDS-defining event
according to the CDC definition19 or a T CD4 cell count de-
cline below 100/mm3 (two repeated measurements). Two
control subjects (i.e., nonprogressors) per case were matched
for age ( 5 years), baseline T CD4 cell count (80/mm3),
and plasma HIV-1 RNA (0.3 log10 copies/ml) ; these pa-
tients did not experience any clinical or biological progres-
sion as defined previously during their first year of HAART.
All eligible cases and controls were selected if they had avail-
able plasma frozen at inclusion, at month 1 (M1), and at
month 4 (M4) follow-up visits.
Measurement of virological and immunological parameters
CD4 counts were measured by flow cytometry and
plasma HIV-1 RNA levels were assessed using the local
available assays, mainly bDNA Chiron 2.0 (detection thresh-
old of 500 copies/ml or 2.7 log10 copies/ml) or PCR by Am-
plicor-Roche (detection threshold of 200 copies/ml or 2.3
log10 copies/ml).
Plasma concentrations of TNF- and its soluble p75 re-
ceptor were measured using specific R&D Systems ELISA
(Nivelles, Belgium), whereas plasma PAF-AH activity and
plasma GSH and GSH-Px levels were quantified using Cay-
man Chemical assays (Ann Arbor, MI). These dosages were
used according to the manufacturer’s recommendations.
Statistical analysis
Comparisons between progressors and nonprogressors
were performed by a Chi-square test for proportions and by
a Wilcoxon test for median values. Evolution of immune
markers was studied between baseline and M4 using a mul-
tivariate linear mixed model making it possible to test for ef-
fect of time and of disease progression. Models were adjusted
for age, history of AIDS, and baseline CD4 cell count,
plasma HIV RNA level, and hemoglobin. Before entering the
values of immune markers in the model, they were loge
transformed to normalize the distribution. Analyses were
performed using the Statistical Analysis System Software
(version 8.2, SAS Institute, Cary, NC).
Results
Study population and baseline characteristics
Among the 26 patients of the APROCO-COPILOTE cohort
who had clinical or laboratory progression during the first
year of follow-up, 22 had a complete collection of frozen
blood samples (baseline, M1, and M4) and were retained in
the analysis as cases: 16 had experienced at least one clini-
cal AIDS-defining event (Table 1) and 6 experienced biolog-
ical progression only (the lowest levels of CD4 lymphocyte
count experienced by these patients were 19, 21, 65, 82, 69,
and 54/mm3). Among the 22 progressors, 8 progressed early
(between M1 and M4) and 14 progressed later (between M4
and M12). Forty-four nonprogressors were appropriately
matched for age, baseline CD4 cell count, and plasma HIV-
1 RNA.
On average, patients were 36 years old and were mainly
infected through sexual contacts (Table 2). The median CD4
cell count was 120/mm3 and HIV-1 RNA 4.5 log10 copies/ml.
Progressors and nonprogressors differed only for median
baseline hemoglobin level, 12.1 vs. 13.8 g/dl, respectively
(p  0.02).
Evolution of laboratory markers during the first 4 months
of HAART
CD4 lymphocyte count. From baseline to M1 and M4, me-
dian CD4 lymphocyte count increased from 125 to 201 (at
M1) and 197/mm3 (at M4) in nonprogressors (p  104) but
only from 113 to 148 (at M1) and 151/mm3 (at M4) in those
patients who rapidly progressed (p  0.22, NS).
Plasma HIV-1 RNA. During the same follow-up period,
median plasma HIV-1 RNA level decreased from 4.6 to 2.7
in nonprogressors (p  103) and from 4.5 to 2.5 log10
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TABLE 1. CLINICAL EVENTS OCCURRING DURING THE FIRST
YEAR OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN 22
CASES, ANRS CO8 APROCO-COPILOTE










Esophageal candidiasis  1
disseminated tuberculosis
Cerebral nocardiosis 1
copies/ml in progressors (p  3.104 ); these decreases were
not statistically different between the two groups (p  0.32).
In nonprogressors, HIV-1 RNA reached undetectable lev-
els (below 2.3 log10 copies/ml) in 33% at M1 and 45% at M4
vs. 37% and 55% in progressors; these variations were not
significantly different between the two groups (p  0.8 and
p  0.5, respectively).
Plasma sR-TNF- p75 and TNF- levels. Among non-
progressors, median plasma sR-TNF- p75 and TNF- de-
creased significantly from baseline to M4: from 11.0 to 8.7
pg/ml [–0.10 loge pg/ml/month (adjusted p  0.001)] and
from 27.3 to 22.8 pg/ml [–0.06 loge pg/ml/month (adjusted
p  0.003)], respectively (Table 3 and Fig. 1). Ajusted p-val-
ues of the variations between M0 and M4 did not change if
undetectability of viral load at M4 was included as an addi-
tional variable in the models. Conversely, no significant de-
crease was observed in progressors (–0.007 loge
pg/ml/month for sR-TNF- p75 and –0.04 loge pg/ml/
month for TNF-).
Among nonprogressors, median plasma sR-TNF- p75 de-
creased significantly from baseline to M4 either in the 19 pa-
tients who achieved viral suppression at M4 or in the 25 who
did not (p  0.001 in both subgroups). Among progressors,
no significant variation of plasma sR-TNF- p75 was ob-
served either in the 12 patients who achieved viral suppres-
sion at M4 or in the 10 who did not.
Finally, the decrease of plasma sR-TNF- p75 between M0
and M4 was larger in nonprogressors than in progressors
(p  0.003) but no significant difference was found for vari-
ations of TNF- between the two groups (Table 3). 
Between M0 and M1 we noticed that the median evolu-
tion of sR-TNF- p75 was –2 pg/ml in nonprogressors and 
0.5 pg/ml in progressors: the differences between these vari-
ations were also highly significant (p  0.01). For TNF- (–3
pg/ml in nonprogressors and –1.8 pg/ml in progressors) no
significant difference was found between the two groups.
Plasma GSH level. A significant increase of plasma GSH
level was observed in nonprogressors from baseline to M4:
3.9–4.6 mol/ml (0.04 loge mol/ml/month, adjusted p 
0.008). No significant evolution was reported in progressors.
Nevertheless, the overall evolution did not differ between
patients who progressed and those who did not progress.
Between M0 and M1 we did not notice significant varia-
tions of median plasma GSH either in nonprogressors (0.5
mol/ml) or in progressors (1 mol/ml) and no signifi-
cant difference was found between the two groups.
Plasma GSH-Px and PAF-AH levels. Plasma GSH-Px did
not significantly change between baseline and M4, either in
nonprogressors (p  0.99) or progressors (p  0.07). Similar
trends were found for the evolution of plasma PAF-AH. No
significant change within or between groups was observed
between M0 and M1 for both markers.
Discussion
The decrease of plasma sR-TNF- p75 was larger in non-
progressors than in progressors while the two groups were
appropriately matched for baseline CD4 lymphocyte count
and plasma HIV-1 RNA and while differences of virological
responses between groups did not explain the differences of
HIV disease progression. As a result of our study design the
sR-TNF- p75 plasma level might be considered as a prog-
nostic marker, in addition to baseline CD4 and plasma HIV
RNA in HAART-treated patients. Whereas the prognostic
value of sR-TNF- p75 plasma level variations within the
first 4 months is obvious, the simultaneous variations of
plasma HIV-RNA did not make it possible to predict HIV
disease progression in our study.
If plasma levels of HIV-RNA and CD4 cell count are
highly predictive of progression to AIDS or death, they do
not explain all the variability of disease progression.3,20,21 We
assume, as do others, that if an additional marker is required
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TABLE 2. BASELINE CHARACTERISTICS OF CASES AND CONTROLS INCLUDED
IN THE ANALYSIS, ANRS CO8 APROCO-COPILOTE
Cases Controls
Progression within Nonprogression
the first year of within the first year of
HAARTa HAARTa
(n  22) (n  44) p
Median age in years (range) 35.1 (28.2–40.7) 37.7 (33.0–40.5) 0.61
HIV transmission category, n (%)
Heterosexuals 9 (40.9) 14 (31.8) 0.62
Men who have sex with men 8 (36.4) 17 (38.6)
Intravenous drug users 3 (13.6) 11 (25.0)
Other 2 (9.1) 2 (4.6)
CDCb clinical stage, n (%)
A 5 (22.7) 17 (38.6) 0.21
B 4 (18.2) 11 (25.0)
C 13 (59.1) 16 (36.4)
Median CD4 cells/mm3 (range) 113 (60–252) 125 (61–249) 0.72
Median HIV1-RNA (log10 copies/ml) (range) 4.5 (3.4–5.5) 4.6 (3.3–5.5) 0.95
Median plasma haemoglobin (g/dl) (range) 12.1 (10.1–13.8) 13.8 (11.9–15.1) 0.02
aHAART, highly active antiretroviral therapy.
bCDC, Centers for Disease Control.
to predict more accurately HIV disease progression, the use
of sR-TNF- p75 might then be taken into account.22
Other inflammatory markers evaluated, i.e., TNF-, PAF-
AH, GSH, and GSH-Px levels, were not associated with dis-
ease progression. Although not established as having a prog-
nostic value, the increase in GSH level in no progressing
patients is nevertheless consistent with the deleterious effect
of glutathione deficiency in progression of HIV disease.15,16
In our study, TNF- plasma level was not associated with
HIV disease progression. TNF- itself may be difficult to de-
tect in the circulation because of its rapid clearance and the
use of assays unable to detect TNF bound to sR-TNF- p75.23
In contrast, sR-TNF- p75 is easily detectable in the plasma
of HIV-infected patients and plasma sR-TNF- p75 may be
considered as a long-term marker of TNF effects.24,25
The limited size and the case–control design of our study
comparing two groups matched for age, baseline CD4
count, and HIV-1 RNA restrict the interpretation of our re-
sults to the additive role of plasma immune markers to al-
ready well-known surrogate markers as we cannot make in-
ferences regarding the intrinsic prognostic role of the
markers. Other observational studies are necessary to con-
firm the prognostic role of sR-TNF- p75 on disease pro-
gression under HAART and to reevaluate those of other in-
flammatory markers, particularly for components of the GSH
system; these further evaluations could also be of value to
assess if markers of immune status, such as CD8 T cell acti-
vation, are prognostic of the failure of HAART, which is still
a controversial issue.26–28 During the chronic phase of HIV
infection, particularly in progressors and even in patients un-
dergoing HAART, the functionality of HIV-specific CD8 T
cells is gradually altered, partly due to persistent antigenic
stimulation and progressive loss of CD4 T cells.29 The TNF
system, by its ability to interfere with HIV replication, apop-
tosis, and T cell activation, could play a major role in this
functionality of CD8 T cells30 and the relationship between
the TNF system and the activation status of CD8 T cells
would then be particularly interesting to study. Concerning
the GSH system, the depletion of GSH and GSH-PX in blood
was confirmed during the acute infection of monkies by
SHIV.31 Nevertheless, even if a correlation was observed be-
tween GSH in blood and lymphocyte proliferative responses
in HIV-infected patients, this correlation is not associated
with variations for HIV viral load and CD4 and CD8
counts.32 Moreover, during chronic infection, no significant
associations were found by Stephensen et al.33 between GSH
and GSH-Px concentrations in blood and the severity of HIV
disease. As a consequence, it seems difficult at present to
consider these elements of the antioxidant defenses as mark-
ers of HAART failure.
MORLAT ET AL.1386
TABLE 3. EVOLUTION OF HIV-1 RNA AND IMMUNE MARKERS BETWEEN BASELINE AND MONTH 4 IN CASES
(PROGRESSION DURING THE FIRST YEAR OF HIGHLY ACTIVE ANTIRETROVIRAL TREATMENT) 
AND CONTROLS (NONPROGRESSION), APROCO-COPILOTE ANRS CO8
Nonprogressor
Progressor group group
(n  22) (n  44) pa
Median HIV-1 RNA log10 copies/ml) (range)
Baseline 4.5 (3.4–5.6) 4.6 (3.3–5.5) 0.95
Month 1 2.7 (2.5–3.8) 2.7 (2.6–3.1) 0.64
Month 4 2.5 (2.3–3.4) 2.7 (2.3–2.7) 0.93
HIV RNA 500 copies/ml, n (%)
Baseline 3 (13.6) 2 (4.6) 0.32
Month 1 8 (36.4) 14 (32.6) 0.76
Month 4 12 (54.6) 19 (45.2) 0.48
Median sR-TNF- p75 (pg/ml) (range)
Baseline 14.1 (8.3–20.3) 11.0 (7.5–22.4) 0.73
Month 1 14.6 (8.3–19.9) 9.0 (6.6–13.8) 0.07
Month 4 11.5 (6.1–20.3) 8.7 (5.9–11.5) 0.05
Median TNF- (pg/ml) (range)
Baseline 35.7 (20.0–44.5) 27.3 (19.9–42.3) 0.53
Month 1 33.9 (23.8–45.4) 24.3 (18.6–35.7) 0.09
Month 4 28.7 (18.6–37.8) 22.8 (18.4–29.2) 0.12
Median PAF-AH (mol/min/ml) (range)
Baseline 10.0 (7.0–12.6) 10.6 (8.2–13.0) 0.72
Month 1 11.8 (7.7–14.0) 10.3 (7.4–12.6) 0.21
Month 4 10.5 (7.9–14.4) 9.9 (8.5–12.8) 0.66
Median GHS (mol/ml) (range)
Baseline 3.9 (2.9–6.1) 4.0 (3.4–5.2) 0.88
Month 1 4.9 (3.4–6.7) 4.5 (3.1–6.1) 0.63
Month 4 4.6 (3.5–6.5) 4.7 (3.4–5.6) 0.82
Median GHS-Px (ng/ml) (range)
Baseline 604 (471–729) 652 (546–800) 0.37
Month 1 609 (376–706) 656 (505–825) 0.11
Month 4 642 (430–728) 700 (568–788) 0.33
aComparison between progressors and nonprogressors.
Our findings may be explained by the relations between
the TNF system and HIV replication. HIV enhances TNF-
production in various cells and, in turn, this activation in-
duces activation of NF-B, enhancing HIV replication
through an amplification circle.34–36 Therefore, the increased
activation of the TNF system may be either the cause or the
result of an increase of HIV-RNA. It has already been sug-
gested that persistent activation of the TNF system may be
involved in treatment failure7 and that decreased TNF ac-
tivity may lead to low-grade viral replication in HAART-
treated patients.5,37 In this context the impact of antiinflam-
matory or anti-TNF drugs might be of interest; thalidomide
induced, in vitro, a decrease of HIV type 1 replication in hu-
man macrophages, but its use for countering oral esophageal
ulcers was not associated with a reduction of plasma levels
of HIV RNA, TNF-, or its soluble receptors.38–40 Conversely,
pentoxiphylline therapy improved constitutional manifesta-
tions and sustained CD4 counts among asymptomatic HIV-
infected individuals.41
If sR-TNF- p75 plasma levels reflect the activation of the
TNF system, we may hypothesize that it also reflects an ac-
tivity of HIV disease that is not explored by the measure-
ment of plasma HIV RNA: in this way activation of inflam-
matory pathways has recently been considered as having a
potential deleterious impact on morbidity in HIV-infected
patients.42 Optimization of antiretroviral therapy might then
be considered in patients with high sR-TN p75 and low
HIV-RNA plasma levels and, conversely, therapeutic reduc-
tions could be assessed in patients with low HIV-RNA and
low sR-TNF- p75 plasma levels.
CD4 cell count is the only immune marker routinely mea-
sured in HIV-infected subjects, but its evolution under treat-
ment is slow and widely varies among HAART-treated pa-
tients. An increase of plasma soluble markers may be an
earlier marker of poor progression by preceding the increase
of HIV RNA and the decrease of CD4 lymphocyte counts
for several months.43 Therefore, our results suggest that
plasma sR-TNF- p75 could be an early marker for treatment
failure, allowing treatment adaptations as soon as possible.
Moreover, CD4 cell count does not reflect the activation sta-
tus of the immune system, although it is of particular inter-
est in the case of discordant immunovirological responses to
treatment, especially when the CD4 count and plasma HIV-
1 RNA are both low. Measurement of plasma sR-TNF- p75
might then be an earlier and additive marker of the im-
munological effect of antiretroviral therapy. If the prognos-
tic value of plasma sR-TNF- p75 level to predict failure of
HAART is confirmed by further evaluations, the use of this
immune marker should be considered during the develop-
ment of new antiretrovirals or immune therapies.
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FIG. 1. Evolution of plasma sR-TNF p75 (with 95% con-
fidence interval) in cases (clinical or laboratory progression
within 1 year after starting highly active antiretroviral ther-
apy) and controls (who did not progress within the first year
of HAART), modeling using a linear mixed model, ANRS
CO8 APROCO-COPILOTE.
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